Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?

Key Points

• Takeda reached a new 52-week high of $18.82 with a market capitalization of about $59.97 billion and its 50‑ and 200‑day simple moving averages at $17.91 and $15.81, respectively.
• The company missed quarterly expectations (EPS $0.48 vs. $0.55 expected; revenue $7.60B vs. $7.81B) and set FY2025 EPS guidance at 3.160, while analysts’ consensus remains an average "Hold" even as Morgan Stanley rates the stock "Overweight."
• Several large investors materially increased positions (Arrowstreet, UBS, Qube, VanEck, Voloridge), signaling notable institutional buying activity, though institutional ownership is around 9.17%.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $18.82 and last traded at $18.7550, with a volume of 353110 shares. The stock had previously closed at $18.52.

Analyst Upgrades and Downgrades

TAK has been the topic of a number of analyst reports. Wall Street Zen cut shares of Takeda Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 3rd. Finally, Morgan Stanley started coverage on Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an "overweight" rating on the stock. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical currently has an average rating of "Hold".

Takeda Pharmaceutical Price Performance

The company has a market capitalization of $59.97 billion, a PE ratio of 78.52 and a beta of 0.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The stock's 50 day simple moving average is $17.91 and its 200-day simple moving average is $15.81.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.07). Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The company had revenue of $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. As a group, equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership grew its stake in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company's stock valued at $88,596,000 after purchasing an additional 2,854,069 shares during the last quarter. UBS Group AG raised its stake in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company's stock worth $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company's stock worth $25,998,000 after purchasing an additional 1,426,184 shares during the period. Van ECK Associates Corp raised its holdings in Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company's stock worth $35,941,000 after purchasing an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC raised its holdings in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company's stock worth $15,005,000 after purchasing an additional 880,289 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.